Three quarterly report disclosures are gradually reaching a climax: the performance of pharmaceutical companies is mixed

Entering October, listed companies have disclosed their third-quarter results, and stocks with outstanding performance have become the focus of investors' attention
.
According to statistics, as of now, more than 110 listed companies in Shanghai and Shenzhen have disclosed their results for the third quarter of 2021.
Among them, nearly 80% of the companies have achieved year-on-year growth in their net profits in the first three quarters
.
Among them, the performance growth companies are mainly concentrated in the four major industries of basic chemicals, electronics, machinery and equipment, and medical and biological industries
.
At present, the disclosure of the third quarter reports of listed companies has gradually reached a climax.
Recently, many pharmaceutical companies have accelerated the release of the third quarter reports, with mixed performances
.
Doray Pharmaceuticals: Net profit decreased by 18.
68% year-on-year.
Doray Pharmaceuticals released its report for the third quarter of 2021 on October 21.
The company achieved main operating income of 396 million yuan, a year-on-year increase of 19.
73%; net profit attributable to the parent company was 49.
344 million yuan, a year-on-year decrease of 18.
68.
%
.
Hengrui Medicine: Net profit decreased by 1.
21% year-on-year.
On the evening of October 19, Hengrui Medicine revealed the third quarter report
.
The report shows that in the first three quarters, Hengrui Pharmaceutical's operating income was 20.
199 billion yuan, a year-on-year increase of 4.
05%, and its parent net profit was 4.
207 billion yuan, a year-on-year decrease of 1.
21%
.
Frontier Bio: Net profit decreased by 8.
38% year-on-year.
Frontier Bio disclosed the first 2021 third quarter report on the Science and Technology Innovation Board on October 15
.
In the first three quarters, the company achieved operating income of 34.
6453 million yuan, a year-on-year increase of 49.
18%; net profit attributable to shareholders of listed companies was 177 million yuan, a year-on-year decrease of 8.
38%
.
Kaipu Bio: Net profit increased by 136.
71% year-on-year.
On October 19, the 2021 third quarter report of Kaipu Biotechnology showed that the company's main operating income was 1.
992 billion yuan, a year-on-year increase of 117.
23%; net profit attributable to the parent company was 647 million yuan, a year-on-year increase of 136.
71%
.
Sinopharm: Net profit increased by 29.
54% year-on-year.
On October 20, Sinopharm released its third quarter report for 2021, showing that the company’s main operating income in the first half of the year was 34.
292 billion yuan, a year-on-year increase of 17.
8%; net profit attributable to the parent was 1.
302 billion yuan, a year-on-year increase of 29.
54%
.
Daan Gene: Net profit growth ceiling is 76%.
On October 13th, Daan Gene disclosed the performance forecast for the first three quarters.
The company expects to achieve net profit attributable to shareholders of listed companies in the first three quarters of 2021 to be 2.
4 billion-2.
7 billion yuan , An increase of 56.
13%-75.
64% over the same period of the previous year; basic earnings per share 1.
7101 yuan / share-1.
9238 yuan / share
.
Zhenghai Biological: Net profit increased by 32.
64% year-on-year.
According to the 2021 third quarter report of Zhenghai Biological, the company's main operating income was 301 million yuan, a year-on-year increase of 39.
26%; the net profit attributable to the parent was 126 million yuan, a year-on-year increase of 32.
64%
.
Mingde Biological: Net profit increase limit 253.
7% Mingde Biological released a performance forecast on October 11, and it is expected that the net profit attributable to the parent in the first three quarters of 2021 will be 970 million yuan to 1.
260 billion yuan, a year-on-year increase of 172.
30% to 253.
70%
.
Since 2020, the company has added more than 1,500 molecular diagnostic-level medical institution customers.
The company has continued to provide comprehensive solutions for nucleic acid detection for the above-mentioned customers, resulting in a significant increase in sales of the company's nucleic acid detection reagents and molecular diagnostic-related instruments
.
Huake Biology: Net profit growth cap of 89.
13% Huake Biology recently released a beautiful first three-quarter performance forecast.
It is expected to achieve a net profit of 690 million yuan to 760 million yuan attributable to shareholders of listed companies, an increase of 71.
71% to 89.
13% year-on-year
.
The company said that the growth in performance is due to the continued growth of market demand for testing, and the company's molecular diagnostics-related business still maintains a good growth trend, resulting in a steady increase in the business of conventional biochemical diagnostics and immunodiagnostic products
.
Special Pharmaceuticals: Net profit growth cap of 255.
09% Special Pharmaceuticals recently released a performance report for the first three quarters of 2021.
During the reporting period, the company achieved operating income of 525 million yuan, a year-on-year increase of 21.
33%; attributable to shareholders of listed companies The deductions before and after non-deduction were 103 million yuan and 89.
43 million yuan respectively, an increase of 257.
54% and 255.
09% year-on-year
.